Latest Articles

Publication Date
Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year - Greater Birmingham Chambers of Commerce

Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year Greater Birmingham Chambers of Commerce

Published: June 12, 2026, 5:07 a.m.
Emerging Pathways to Non-Invasive Diagnosis in Endometriosis: Integrating Machine Learning, Deep Learning and Multi-Omics Biomarkers.

Endometriosis is a chronic, debilitating condition affecting approximately 10-15% of reproductive-aged women and it is often associated with significant diagnostic delays due to its heterogeneity and unreliable non-invasive tests. Artificial …

Published: June 12, 2026, midnight
Epidemiology, Risk Factors, Diagnosis, and Comorbidities of Endometriosis: An Umbrella Review.

Background: Endometriosis is a chronic estrogen-dependent inflammatory disease estimated to affect up to 190 million women of reproductive age worldwide based on clinical and population-based estimates, although only 22.3 million …

Published: June 12, 2026, midnight
The role of IL-33/ST2 signaling in female reproductive diseases.

Female reproductive tissues repeatedly undergo controlled inflammation, immune adaptation, and tissue repair. Interleukin-33 (IL-33) and its receptor suppression of tumorigenicity 2 (ST2) sit at the center of these processes, but …

Published: June 12, 2026, midnight
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com

Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates marketscreener.com

Published: June 11, 2026, 1:52 p.m.
Oriva appoints Agnès Arbat as CEO as endometriosis drug enters clinic - The Pharma Letter

Oriva appoints Agnès Arbat as CEO as endometriosis drug enters clinic The Pharma Letter

Published: June 11, 2026, 12:10 p.m.
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Nigeria

Medicus Pharma submits IND application for endometriosis trial By Investing.com Investing.com Nigeria

Published: June 11, 2026, 11:58 a.m.
Medicus Pharma submits IND application for endometriosis trial - Investing.com

Medicus Pharma submits IND application for endometriosis trial Investing.com

Published: June 11, 2026, 11:55 a.m.
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Canada

Medicus Pharma submits IND application for endometriosis trial By Investing.com Investing.com Canada

Published: June 11, 2026, 11:41 a.m.
Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis - Quiver Quantitative

Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis Quiver Quantitative

Published: June 11, 2026, 11:41 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!